FGD3 mRNA expression as a biomarker for an immune response was evaluated by using tumor-infiltrating lymphocyte cells in TCGA breast cancer and Breast International Group 1-98 (BIG 1-98; Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer) cohorts. Here, FGD3 is linked to breast carcinoma.